These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37661888)

  • 1. Pathway-Specific Polygenic Risk Scores Correlate with Clinical Status and Alzheimer's Disease-Related Biomarkers.
    Schork NJ; Elman JA;
    J Alzheimers Dis; 2023; 95(3):915-929. PubMed ID: 37661888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathway-specific polygenic risk scores correlate with clinical status and Alzheimer's-related biomarkers.
    Schork NJ; Elman JA
    Res Sq; 2023 Mar; ():. PubMed ID: 36909609
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of
    Xicota L; Gyorgy B; Grenier-Boley B; Lecoeur A; Fontaine G; Danjou F; Gonzalez JS; Colliot O; Amouyel P; Martin G; Levy M; Villain N; Habert MO; Dubois B; Lambert JC; Potier MC;
    Neurology; 2022 Aug; 99(5):e462-e475. PubMed ID: 35606148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.
    Darst BF; Koscik RL; Racine AM; Oh JM; Krause RA; Carlsson CM; Zetterberg H; Blennow K; Christian BT; Bendlin BB; Okonkwo OC; Hogan KJ; Hermann BP; Sager MA; Asthana S; Johnson SC; Engelman CD
    J Alzheimers Dis; 2017; 55(2):473-484. PubMed ID: 27662287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-Related Biomarkers Among Asymptomatic Individuals.
    Xu Y; Vasiljevic E; Deming YK; Jonaitis EM; Koscik RL; Van Hulle CA; Lu Q; Carboni M; Kollmorgen G; Wild N; Carlsson CM; Johnson SC; Zetterberg H; Blennow K; Engelman CD
    J Alzheimers Dis; 2023; 94(4):1587-1605. PubMed ID: 37482996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polygenic effects on the risk of Alzheimer's disease in the Japanese population.
    Kikuchi M; Miyashita A; Hara N; Kasuga K; Saito Y; Murayama S; Kakita A; Akatsu H; Ozaki K; Niida S; Kuwano R; Iwatsubo T; Nakaya A; Ikeuchi T; ;
    Alzheimers Res Ther; 2024 Feb; 16(1):45. PubMed ID: 38414085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome.
    Gorijala P; Aslam MM; Dang LT; Xicota L; Fernandez MV; Sung YJ; Fan KH; Feingold E; Surace EI; Chhatwal JP; Hom CL; ; ; Hartley SL; Hassenstab J; Perrin RJ; Mapstone M; Zaman SH; Ances BM; Kamboh MI; Lee JH; Cruchaga C
    Alzheimers Dement; 2024 Feb; 20(2):1038-1049. PubMed ID: 37855447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.
    Kumar A; Janelidze S; Stomrud E; Palmqvist S; Hansson O; Mattsson-Carlgren N;
    Neurology; 2022 Aug; 99(5):e476-e487. PubMed ID: 35641311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's polygenic risk scores, APOE, Alzheimer's disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years.
    Stocker H; Trares K; Beyer L; Perna L; Rujescu D; Holleczek B; Beyreuther K; Gerwert K; Schöttker B; Brenner H
    Alzheimers Res Ther; 2023 Jul; 15(1):129. PubMed ID: 37516890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Pathway-specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals.
    Xu Y; Vasiljevic E; Deming YK; Jonaitis EM; Koscik RL; Van Hulle CA; Lu Q; Carboni M; Kollmorgen G; Wild N; Carlsson CM; Johnson SC; Zetterberg H; Blennow K; Engelman CD
    medRxiv; 2023 Feb; ():. PubMed ID: 36778431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition.
    Leonenko G; Shoai M; Bellou E; Sims R; Williams J; Hardy J; Escott-Price V;
    Ann Neurol; 2019 Sep; 86(3):427-435. PubMed ID: 31199530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Differential Influence of Immune, Endocytotic, and Lipid Metabolism Genes on Amyloid Deposition and Neurodegeneration in Subjects at Risk of Alzheimer's Disease.
    Femminella GD; Harold D; Scott J; Williams J; Edison P;
    J Alzheimers Dis; 2021; 79(1):127-139. PubMed ID: 33216025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Polygenic Risk Score and the Progression from Mild Cognitive Impairment to Alzheimer's Disease.
    Liu H; Lutz M; Luo S;
    J Alzheimers Dis; 2021; 84(3):1323-1335. PubMed ID: 34657885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polygenic risk scores for Alzheimer's disease in relation to cognitive change: A representative sample from the general population followed over 16 years.
    Najar J; Thorvaldsson V; Kern S; Skoog J; Waern M; Zetterberg H; Blennow K; Skoog I; Zettergren A
    Neurobiol Dis; 2023 Dec; 189():106357. PubMed ID: 37977433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden.
    Ramanan VK; Heckman MG; Przybelski SA; Lesnick TG; Lowe VJ; Graff-Radford J; Mielke M; Jack CR; Knopman DS; Petersen RC; Ross OA; Vemuri P;
    J Alzheimers Dis; 2022; 88(4):1615-1625. PubMed ID: 35811524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment.
    Pyun JM; Park YH; Lee KJ; Kim S; Saykin AJ; Nho K;
    Transl Neurodegener; 2021 Aug; 10(1):32. PubMed ID: 34465370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of clinical diagnosis of Alzheimer's disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years.
    Stocker H; Perna L; Weigl K; Möllers T; Schöttker B; Thomsen H; Holleczek B; Rujescu D; Brenner H
    Mol Psychiatry; 2021 Oct; 26(10):5812-5822. PubMed ID: 32404947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer's Disease.
    Daunt P; Ballard CG; Creese B; Davidson G; Hardy J; Oshota O; Pither RJ; Gibson AM
    J Prev Alzheimers Dis; 2021; 8(1):78-83. PubMed ID: 33336228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Polygenic Scores to Precision Medicine in Alzheimer's Disease: A Systematic Review.
    Harrison JR; Mistry S; Muskett N; Escott-Price V
    J Alzheimers Dis; 2020; 74(4):1271-1283. PubMed ID: 32250305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.